U.S. Markets closed

OncoMed Pharmaceuticals, Inc. (OMED)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.68+0.16 (+4.55%)
At close: 4:00PM EDT
People also watch
  • They are 0 for 3 so far...what makes you people think any of the other drugs in their pipeline are any good??
  • Huge spike in volume & price yesterday.
  • Folkd, Below is the perfect example:

    Media headlines about Oncomed Pharmaceuticals (NASDAQ:OMED) have trended somewhat positive recently, Alpha One Sentiment Analysis reports. The research group, a unit of Accern, rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a news impact score of 0.03 on Alpha One’s scale. Alpha One also gave news headlines about the biopharmaceutical company an impact score of 60 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the company’s share price in the near term.
  • Folks, Yesterday evening, the key OMED's analyst, Mr. Shaunak Deepak from H.C. Wainwright fund management just changed his recommendation from "HOLD" to "BUY". This is another example of this stock upward movement!
    But, we have not seen anything, yet. Stay tuned for take-off!

  • Dear all, My relative is indicating, there might be a quick take-over by Celgene Corporation (CELG). Looks like, the company has enough cash to pay for itself. In addition, CELG gets all those patents and those unbelievable talents FREE. Think about this? It make perfect sense. Doesn't it?
  • Tonight, one more analyst will be changing her recommendation from "HOLD" to "BUY"! Stay tuned.
  • Please check below for increased in institutional-holdings:


    OncoMed Pharmaceuticals, Inc. (OMED) Institutional Ownership & Holdings
    Detailed institutional ownership and holders of OncoMed Pharmaceuticals, Inc. (OMED), including new, increased, descreased, and sold out positions.
  • One more trial blew up as per the cc this morning.

    Don't expect any significant data until mid to late 2018.

    So why should I buy this?
  • Dear all, This news came today, around 7 hours ago:
    OncoMed Pharmaceuticals, Inc. (OMED) Consensus Price Target
    The company’s consensus rating on Reuter’s scale improved from 1.89 to 2.38 during a month. Analysts set a 12-month price target of $7.29 a share. The target implies a 98.64% spike from where the shares are currently trading. Also, the current price highlights a discount of 199.73% to analysts’ high consensus price target.
  • Today's selling is from 2 institutions which they needed their money for another investment that they are planning to do. It has nothing to do with OMED itself.
  • I still feel good about this stock, long term. Yes. I really do.
  • Folks, I have done analysis and I feel very good about this stock. I have entered at 4.01 and will add as soon as I see further potential. I NEVER average down.. BUT, always, average up! Comments, please...
  • Latest article "SmallCap Exclusive":
    written by Richard Schwarz April 27, 2017"
  • Folks, This company has aligned internal resources with an eye to boosting the likelihood of getting more cash via milestone payments, including those with Celgene for early-stage work on rosmantuzumab, navicixizumab and OMP-313M32, which could be worth nearly $100 million over the next two years. The company's spokesman said it will also seek to “maximize the value from potential interest in partnering the assets to which it has worldwide rights, such as vantictumab, ipafricept, GITRL-Fc trimer and undisclosed immuno-oncology discoveries". In addition, Paul Hastings, OncoMed’s chairman and CEO, said: “With this restructuring, we expect to have greater than two years’ cash to support operations focused on driving our rosmantuzumab, navicixizumab and anti-TIGIT clinical-stage programs to $98 million in potential development milestone payments while advancing our immuno-oncology discovery-stage portfolio. We plan to also explore partnering opportunities for our Wnt pathway and immuno-oncology agents to which we have worldwide rights.”
  • Buying opportunity soon?
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%+ POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Holding too many drugs in pipeline and ventures with other pharma
  • Missed their mark on the trial... get out while you can!
  • What are the chances this thing could bounce back in the next 6 mos? Any other notable events on the horizon?
  • it would be interesting to see what happens... when they ran out of cash later this year....